Stock MXCT MAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials MaxCyte, Inc. Nasdaq

Equities

MXCT

US57777K1060

Advanced Medical Equipment & Technology

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-14 pm EDT 		5-day change 1st Jan Change
4.9 USD -1.01% Intraday chart for MaxCyte, Inc. +0.82% +4.26%
Jun. 11 MaxCyte CEO Maher Masoud buys 100,000 shares AN
Jun. 11 Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 95.12 556.7 1,034 541 466 503.8 - -
Enterprise Value (EV) 1 83.31 526.9 778.7 313.6 297.7 354.2 383.8 405.3
P/E ratio -7.21 x -42.4 x -48.6 x -23 x -12.1 x -10.6 x -11.4 x -15.4 x
Yield - - - - - - - -
Capitalization / Revenue 4.4 x 21.3 x 30.5 x 12.2 x 11.3 x 13.8 x 10.8 x 7.7 x
EV / Revenue 3.85 x 20.1 x 23 x 7.09 x 7.21 x 9.73 x 8.23 x 6.19 x
EV / EBITDA -7.06 x -52.6 x -44.7 x -12.7 x -6.75 x -7.1 x -9.04 x -17.4 x
EV / FCF - - -53.7 x -9.43 x -11.7 x -6.04 x -6.56 x -8.68 x
FCF Yield - - -1.86% -10.6% -8.53% -16.5% -15.2% -11.5%
Price to Book - - - - - 2.48 x 2.8 x 2.91 x
Nbr of stocks (in thousands) 57,389 77,185 101,203 102,230 103,860 104,544 - -
Reference price 2 1.658 7.213 10.21 5.292 4.487 4.819 4.819 4.819
Announcement Date 4/21/20 4/20/21 3/22/22 3/15/23 3/12/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 21.62 26.17 33.89 44.26 41.29 36.42 46.63 65.45
EBITDA 1 -11.81 -10.01 -17.42 -24.79 -44.13 -49.86 -42.44 -23.33
EBIT 1 -12.42 -11.06 -18.19 -27.36 -48.3 -57.16 -51.62 -40.28
Operating Margin -57.44% -42.25% -53.66% -61.82% -116.98% -156.97% -110.69% -61.54%
Earnings before Tax (EBT) 1 -12.9 -11.82 -19.08 -23.57 -37.92 -47.23 -42.12 -33.84
Net income 1 -12.9 -11.82 -19.08 -23.57 -37.92 -48.67 -44.97 -33.86
Net margin -59.64% -45.15% -56.3% -53.25% -91.85% -133.65% -96.43% -51.73%
EPS 2 -0.2300 -0.1700 -0.2100 -0.2300 -0.3700 -0.4565 -0.4209 -0.3127
Free Cash Flow 1 - - -14.51 -33.26 -25.39 -58.6 -58.48 -46.7
FCF margin - - -42.82% -75.14% -61.49% -160.92% -125.41% -71.35%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 4/21/20 4/20/21 3/22/22 3/15/23 3/12/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 10.89 10.15 11.59 9.608 10.64 12.42 8.576 9.043 8.004 15.67 11.34 7.971 8.383 8.908 10.1 10.64
EBITDA 1 - -4.538 -3.672 -8.191 -7.085 -5.842 -12.22 -12.05 -12.87 -6.993 -11.16 -12.82 -12.8 -13.14 -11.35 -11.01
EBIT 1 - -4.955 -4.159 -8.739 -7.712 -6.75 -13.18 -13.07 -13.95 -8.095 -12.28 -15.17 -14.88 -14.92 -14.22 -13.9
Operating Margin - -48.81% -35.89% -90.96% -72.46% -54.33% -153.65% -144.58% -174.31% -51.67% -108.23% -190.26% -177.49% -167.46% -140.86% -130.62%
Earnings before Tax (EBT) 1 - - -4.067 -8.26 -6.434 -4.809 -10.88 -10.51 -11.25 -5.277 -9.526 -12.47 -12.26 -12.55 -12.72 -12.38
Net income 1 - -4.874 -4.067 -8.26 -6.434 -4.809 -10.88 -10.51 -11.25 -5.277 -9.526 -13.18 -12.95 -13.02 -12.66 -12.38
Net margin - -48.01% -35.1% -85.97% -60.45% -38.71% -126.88% -116.25% -140.57% -33.68% -83.99% -165.4% -154.53% -146.14% -125.39% -116.3%
EPS 2 -0.1000 -0.0500 -0.0400 -0.0800 -0.0600 -0.0500 -0.1100 -0.1000 -0.1100 -0.0500 -0.0900 -0.1229 -0.1200 -0.1200 -0.1175 -0.1175
Dividend per Share - - - - - - - - - - - - - - - -
Announcement Date 9/21/20 3/22/22 5/9/22 8/10/22 11/9/22 3/15/23 5/10/23 8/9/23 11/8/23 3/12/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 11.8 29.8 255 227 168 150 120 98.5
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - -14.5 -33.3 -25.4 -58.6 -58.5 -46.7
ROE (net income / shareholders' equity) - - - - - -21.6% -20.6% -13.4%
ROA (Net income/ Total Assets) - - - - - -18.5% -17.4% -11.1%
Assets 1 - - - - - 262.8 258.5 304.6
Book Value Per Share 2 - - - - - 1.940 1.720 1.660
Cash Flow per Share 2 - - - - - -0.2300 -0.2400 -0.0700
Capex 1 1.27 2.07 3.83 18.5 3.7 4.77 5.52 6.24
Capex / Sales 5.88% 7.92% 11.31% 41.75% 8.96% 13.11% 11.84% 9.54%
Announcement Date 4/21/20 4/20/21 3/22/22 3/15/23 3/12/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for MaxCyte, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.819 USD
Average target price
6.94 USD
Spread / Average Target
+44.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.77% 218B
DANAHER CORPORATION Stock Danaher Corporation
+10.16% 189B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+26.21% 151B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+32.78% 113B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.98% 64.02B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.48% 52.6B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+2.92% 49.85B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-6.60% 37.89B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
-1.07% 34.92B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. MXCT Stock
  4. MXCT Stock
  5. Financials MaxCyte, Inc.